A detailed history of Aqr Capital Management LLC transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Aqr Capital Management LLC holds 30,869 shares of CRDF stock, worth $131,193. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,869
Holding current value
$131,193
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.05 - $2.77 $63,281 - $85,507
30,869 New
30,869 $82,000
Q2 2022

Aug 15, 2022

SELL
$1.17 - $2.61 $361,182 - $805,714
-308,703 Reduced 84.98%
54,580 $120,000
Q1 2022

May 16, 2022

BUY
$2.11 - $7.25 $696,312 - $2.39 Million
330,006 Added 991.69%
363,283 $901,000
Q4 2021

Feb 14, 2022

SELL
$5.18 - $7.24 $14,379 - $20,098
-2,776 Reduced 7.7%
33,277 $200,000
Q3 2021

Nov 15, 2021

BUY
$5.01 - $7.58 $180,625 - $273,281
36,053 New
36,053 $240,000

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $184M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.